- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01204138
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA (CATARA)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The primary objective of this study is to evaluate the efficacy of apremilast when used in combination with a background DMARD and TNF inhibition in patients with active RA using the ACR responder index looking for a 20% improvement.
To evaluate the safety and tolerability of apremilast when used in combination with TNF inhibition in patients with active RA.
To evaluate the clinical outcomes in RA using the individual domains of the ACR responder index1 .
To evaluate the clinical outcomes of RA using the Disease Activity Score (DAS28)2 To investigate the effects of apremilast on change in cytokine plasma concentration levels (from baseline to Week 12) and the achievement of an ACR response
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
Stanford, California, États-Unis, 94305
- Stanford University School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form
- 18 years of age at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements
- Must have a diagnosis of RA of at least 6 months duration based on the ACR criteria
- Must have evidence of active disease with DAS-28 > 3.8
May be on one of the following DMARDs for at least 12 weeks and at a stable dose for at least 6 weeks:
- Methotrexate 7.5-25mg/week
- Hydroxychloroquine (200-400mg/day)
Must be on one of the following SQ TNF inhibitors at a stable, label approved dose for at least 12 weeks:
- adalimumab (Humira®, Abbott Laboratories, North Chicago, IL)
- certolizumab pegol (Cimzia®, UCB, Inc, Smyrna, GA)
- golimumab (Simponi®, Johnson & Johnson, New Brunswick, NJ)
- etanercept (Enbrel®, Amgen, Thousand Oaks, CA and Wyeth Pharmaceuticals, Philadelphia, PA)
- Concommitant use of non-steroidal anti-inflammatory drugs and/or oral corticosteroids (prednisone<10mg/day or equivalent) are permitted if doses have been stable for at least 14 days.
- If taking methotrexate, patient must also be taking folic or folinic acid at at dose of no less then 5mg/week.
Must meet the following laboratory criteria:
- Hemoglobin > 9 g/dL
- White blood cell (WBC) count; 3000 /;L (3.0 X 109/L) and 14,000/L (< 14 X 109/L)
- Platelets; 100,000 /L (100 X 109/L)
- Serum creatinine; 1.5 mg/dL (or 133mol/L)
- Total bilirubin; 2.0 mg/dL
- Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]); 1.5x upper limit of normal (ULN)
- Females of childbearing potential (FCBP)‡ must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO of the following adequate forms of contraception while on study medication: oral, injectable, or implantable hormonal contraceptives; tubal ligation; intrauterine device; barrier contraceptive with spermicide; or vasectomized partner while on study. A FCBP must agree to have pregnancy tests every 4 weeks while on study medication and for one month after taking the last dose of study medication.
- Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP while on study medication and for 28 days after taking the last dose of study medication
Exclusion Criteria:
- Inability to provide voluntary consent
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Pregnant or breastfeeding
- Systemic fungal infection
- Active tuberculosis or a history of incompletely treated tuberculosis
- History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years)
- Clinically significant abnormality on the chest x-ray (CXR) with anteriorposterior and lateral views at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable.
- Use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer)
- Any clinically significant abnormality on 12-lead ECG at screening
- History of congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency [CVID])
- Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening
- History of Human Immunodeficiency Virus (HIV) infection
- Antibodies to Hepatitis C at screening
- History of malignancy within 5 years prior to the screening visit (except for treated [i.e. cured] basal cell skin carcinomas and treated [i.e. cured] carcinoma in situ of the cervix)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: placebo
Patient randomized to one of two arms, either placebo, or Apremilast
|
Placebo BID
|
Comparateur actif: Apremilast
Patients randomized to either placebo or apremilast
|
Apremilast 30mg BID
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
20% improvement based on ACR responder criteria
Délai: 12 weeks
|
12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
ACR 50/70 and DAS
Délai: 12 weeks
|
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Mark Genovese, Stanford University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Maladies auto-immunes
- Maladies articulaires
- Maladies musculo-squelettiques
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Arthrite
- Arthrite, rhumatoïde
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Inhibiteurs de la phosphodiestérase
- Inhibiteurs de la phosphodiestérase 4
- Aprémilast
Autres numéros d'identification d'étude
- SU-08312010-6811
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
Regado Biosciences, Inc.ComplétéVolontaire en bonne santéÉtats-Unis